Mabpharm Ltd (2181) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Mabpharm Ltd HK$0.13, price HK$0.45, upside -71.1%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Mabpharm Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range HK$0.2500 – HK$1.31 · fair‑value band HK$0.0700 – HK$0.2300 · the HK$0.4500 price screens above the HK$0.1300 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Mabpharm in your weekly email
Every Wednesday you see whether Mabpharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People's Republic of China.
Show more
Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People's Republic of China. It offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment of ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, Crohn's disease in adults and pediatric patients aged above 6 years old, fistula Crohn's disease, and psoriasis. The company also develops CMAB807/CMAB807X that has completed Phase III clinical trial for the treatment of osteoporosis, tumor bone metastasis, and giant-cell tumor of bone; CMAB819 that has completed Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis that is in Phase I clinical trial. In addition, its products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB016, a biosimilar product candidate of dupilumab for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), and prurigo nodularis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab. Further, the company is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, chemical biological reagents, diagnostic reagents, and drugs. Mabpharm Limited was incorporated in 2018 and is headquartered in Taizhou, China.
Stock analysis
Mabpharm Ltd (2181) currently trades at HK$0.4500, while our model-based Fair Value estimate is HK$0.1300, 71.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$0.7300 per share, and 4 of the 15 models we run sit above the HK$0.4500 price.
Bear case: the Economic Profit group reads lowest at HK$0.0200, and 11 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.0700 (bear) to HK$0.2300 (bull), the price of HK$0.4500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Mabpharm Ltd reported revenue of 629M CNY in FY2025 versus 82.9M CNY in FY2021, a compound +66.0%/yr. Reported net income was 55.7M CNY in FY2025.
Key figures
Market cap HK$1.9B (≈ $237M) · P/E ratio 42.0 · P/S ratio 3.71 · Net margin 8.8% · Return on equity 46.4% · Return on assets (EBIT) −17.7% · Operating margin 0.5% · Revenue (TTM) 646M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −71%, 2181 screens richer than that median.
Fair Value models
Bear HK$0.0700Fair Value HK$0.1300Bull HK$0.2300
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+143.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+124.1%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.5%
’17
’18
’19
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,384.4% (2019) → 0.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−71.1% · Below median
Profitability
Return on equity (TTM)46.4% · Top 25%
Return on assets0.3% · Above median
Net margin (TTM)8.8% · Above median
Operating margin (TTM)0.5% · Above median
Growth and dividend
Revenue growth148.4% · Top 25%
Balance sheet
Debt / equity0.42× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)42.0× · Pricier than median
P/B10.07× · Priciest 25%
P/S (TTM)2.45× · Cheaper than median
EV/EBITDA26.0× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)79· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Mabpharm Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2181
Frequently asked questions
Is Mabpharm Ltd (2181) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.1300 versus a price of HK$0.4500, about −71% upside (overvalued).
What is the fair value of 2181?
Our model-based fair value for Mabpharm Ltd is HK$0.1300 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.4500.
What is the quality score of 2181?
Mabpharm Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mabpharm Ltd (2181)?
Our model-based price target is the fair value of HK$0.1300 (as of Sep 27, 2026) from 15 valuation models. Cautious scenario HK$0.0700, optimistic scenario HK$0.2300. It is a calculation from audited fundamentals, not an analyst target.
What is the Mabpharm Ltd stock forecast for 2026?
Our models put fair value at HK$0.1300, about −71% upside versus a price of HK$0.4500 (overvalued). Cautious scenario HK$0.0700, optimistic scenario HK$0.2300. The calculation is refreshed regularly with new filings.
What is the revenue of Mabpharm Ltd (2181)?
Mabpharm Ltd reported trailing-twelve-month revenue of about 646M CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Mabpharm Ltd (2181)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mabpharm Ltd it is HK$0.1300 per share (as of Sep 27, 2026), against a price of HK$0.4500. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Mabpharm Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2181 trades above its calculated fair value: price HK$0.4500, fair value HK$0.1300, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2181?
No. The price is what the market pays today (HK$0.4500); the fair value is what the company's own numbers justify (HK$0.1300). For Mabpharm Ltd the two are HK$0.3200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mabpharm Ltd worth?
The market values Mabpharm Ltd at about HK$1.9B (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.4500; our models calculate a fair value of HK$0.1300 per share.
What do the bullish and bearish scenarios say about 2181?
Our models span a range for Mabpharm Ltd: cautious scenario HK$0.0700, base HK$0.1300, optimistic HK$0.2300 per share (as of Sep 27, 2026, price HK$0.4500). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2181?
Mabpharm Ltd trades at a price-to-earnings ratio of 42.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.1300 is built from several models across several years. Other multiples: P/B 10.1, P/S 2.5, EV/EBITDA 26.0.
How solid is the balance sheet of Mabpharm Ltd (2181)?
Balance-sheet figures for Mabpharm Ltd (as of Sep 27, 2026): return on equity 46.4%, debt of 0.42 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 2181 from its 52-week high?
Mabpharm Ltd trades at HK$0.4500, about 38% below its 52-week high of HK$0.7200 and 22% above the low of HK$0.3700 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1300 is for.
Which stocks are comparable to Mabpharm Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mabpharm Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.4500, calculated fair value HK$0.1300 (−71%), Quality Score 54/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2181 calculated?
We run Mabpharm Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.1300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Mabpharm Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mabpharm Ltd (2181)?
The closing price on Sep 30, 2026 was HK$0.4500. Our model-based fair value is HK$0.1300, about −71% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mabpharm Ltd right now?
The price sits above even our optimistic bull case (HK$0.2300). The favourable scenario is already priced in. The model range is unusually wide (HK$0.0700 to HK$0.2300). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Mabpharm Ltd
How large is the market capitalisation of Mabpharm Ltd (2181)?
The market capitalisation of Mabpharm Ltd is HK$1.9B (≈ $237M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mabpharm Ltd (2181)?
The price-to-sales ratio of Mabpharm Ltd is 3.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Mabpharm Ltd (2181)?
The net margin of Mabpharm Ltd is 8.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mabpharm Ltd (2181)?
The return on equity (ROE) of Mabpharm Ltd is 46.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mabpharm Ltd (2181)?
On an EBIT basis the return on assets of Mabpharm Ltd is −17.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mabpharm Ltd (2181)?
The operating margin of Mabpharm Ltd is 0.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mabpharm Ltd (2181)?
Revenue at Mabpharm Ltd is growing +148% versus a year earlier (3y avg +124%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Mabpharm Ltd (2181) generate?
The free cash flow of Mabpharm Ltd is −23.2M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mabpharm Ltd (2181) carry?
The net debt of Mabpharm Ltd is 218M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mabpharm Ltd in the live analysis
One click puts Mabpharm Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
